AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 291 min read$ALKS

Parisi Samuel Joseph sold $687K of ALKS

Parisi Samuel Joseph (VP, Finance (Interim PAO)) sold 16,217 shares of Alkermes plc. (ALKS) at $42.36 ($0.69M total) on 2026-05-29.

Original reporting
SEC EDGAR · Parisi Samuel Joseph
Published May 29, 2026, 10:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALKS
Bearish
medium confidence
Mentioned
$ALKS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSBearishLow
01

Why it matters

The disclosure updates insider activity records; it may slightly influence short-term sentiment but does not introduce new company fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale is unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

No 10b5-1 plan is cited, but the filing still lacks context (e.g., diversification, tax obligations, pre-scheduled personal events), limiting inference about future fundamentals.

Relevance 6/10Novelty 6/10Timing: Filed same day (2026-05-29) as the sale date, for immediate awareness.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Alkermes (ALKS).

Company-level read

Ticker impact

$ALKSBearishMedium confidence
Context

Alkermes (ALKS) is the issuer of an SEC Form 4 showing VP Finance Parisi Samuel Joseph sold 16,217 shares on 2026-05-29.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional insider selling or company-specific news.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated; however, insider sales are common and the article provides no new operating/clinical/financial information.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical read-across provided.

Regional

None indicated; US-listed issuer only.

Global

None indicated; no cross-border deal/regulatory action mentioned.

Counterpoint

What could challenge this read

The sale could be liquidity/tax-driven and not a bearish view, especially since insider transactions often occur for non-informational reasons.

Key entities

  • issuer
    Alkermes plc

    Subject company for the SEC Form 4 insider sale disclosed on 2026-05-29.

  • insider
    Parisi Samuel Joseph

    VP, Finance (Interim PAO) who sold 16,217 ALKS shares for ~$687k.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALKS insider trading history →

Related articles

AUG 28
$ALKSMedAI 8/10

Phase 2 Data on Investigational Narcolepsy Drug Published

Alkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.

sleepreviewmag.com2 min
AUG 27
$ALKSMedAI 9/10

Did Positive Vibrance-1 Data and Brilliance Phase 3 Launch Just Shift Alkermes' (ALKS) Investment Narrative?

Alkermes (ALKS) reported positive Phase 2 data for alixorexton in narcolepsy, leading to a global Phase 3 trial launch. The data, published in The Lancet Neurology, showed significant improvements in wakefulness and safety. The company aims for $2.3B revenue by 2029, with analysts projecting up to $2.8B. Success hinges on Phase 3 trial outcomes.

simplywall.st2 min
AUG 25
$ALKSMedAI 8/10

Alkermes plc: The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Alkermes (ALKS) announced positive phase 2 study results for alixorexton in adults with narcolepsy type 1, published in The Lancet Neurology. The study showed statistically significant improvements in wakefulness and cataplexy, with all doses well-tolerated. Alkermes has initiated phase 3 trials for alixorexton in narcolepsy types 1 and 2.

finanznachrichten.de2 min